TG Therapeutics Inc Earnings

The next earnings date for TG Therapeutics Inc is October 30, 2025.

They are scheduled to announce earnings after the market closes that day.

Analyst Estimates of TG Therapeutics Inc Earnings

Report DateEstimated Earnings Per Share
10/30/2025$0.22

What is an Earnings Date

An earnings date is typically considered to be the date that a company publicly announces its earnings. Many companies in the US stock market do earnings announcements once per quarter.

Earnings announcements are typically accompanied by commentary from the company that explains the earnings performance and speaks to future earnings prospects.

Earnings announcements can cause a company’s stock price to change abruptly, so earnings dates are closely monitored by some investors.

TG Therapeutics Inc Earnings: Historical

Report DateBefore/After MarketEarnings Per ShareSurprise %
08/05/2025---$0.17-8.70%
04/29/2025Before Market$0.03-82.76%
02/26/2025Before Market$0.1566.67%
11/04/2024Before Market$0.02-33.33%
08/06/2024Before Market$0.04180.00%
05/01/2024Before Market$-0.07-75.00%
02/28/2024Before Market$-0.100.00%
11/01/2023Before Market$0.73508.33%
08/01/2023Before Market$-0.34-36.00%
05/01/2023Before Market$-0.2824.32%
02/28/2023Before Market$-0.39-50.00%
11/09/2022After Market$-0.2623.53%
08/08/2022Before Market$-0.3041.18%
05/10/2022After Market$-0.5113.56%
03/01/2022Before Market$-0.70-11.11%
11/04/2021Before Market$-0.65-16.07%
08/02/2021Before Market$-0.59-18.00%
05/10/2021Before Market$-0.69-40.82%
03/01/2021After Market$-0.71-22.41%
11/09/2020After Market$-0.61-48.78%
08/10/2020Before Market$-0.47-38.24%
05/11/2020After Market$-0.48-33.33%
03/02/2020After Market$-0.444.35%
11/12/2019Before Market$-0.69-102.94%
08/09/2019Before Market$-0.42-2.44%
05/10/2019Before Market$-0.430.00%
03/01/2019After Market$-0.69-56.82%
11/09/2018Before Market$-0.4320.37%
08/07/2018After Market$-0.59-13.46%
05/08/2018Before Market$-0.59-34.09%
03/08/2018Before Market$-0.46-4.55%
11/08/2017Before Market$-0.48-11.63%
08/09/2017Before Market$-0.45-4.65%
05/05/2017Before Market$-0.52-36.84%
03/10/2017Before Market$-0.48-33.33%
11/07/2016Before Market$-0.50-61.29%
08/08/2016Before Market$-0.33-17.86%
05/10/2016After Market$-0.2822.22%
03/07/2016After Market$-0.37-15.63%
11/09/2015Before Market$-0.2817.65%
08/10/2015Before Market$-0.38-26.67%
05/04/2015After Market$-0.39-18.18%
03/11/2015After Market$-0.253.85%
11/10/2014After Market$-0.51-59.38%
07/21/2014---$-0.32-33.33%
05/12/2014---$-0.25-38.89%
03/05/2014---$-0.19-11.76%
11/11/2013---$-0.1627.27%
08/01/2013---$-0.29-81.25%
05/14/2013---$-0.17-13.33%
03/12/2013---$-0.127.69%
11/08/2012---$-0.16-33.33%
08/09/2012---$-0.16-166.67%
05/21/2012---$-2.03---
11/14/2011---$-9.05---
08/15/2011---$-64.63---
05/23/2011---$84.58---
03/02/2011---$9.18---
11/15/2010---$0.96---
08/16/2010---$43.21---
05/24/2010---$-54.27---
03/03/2010---$-8.88---
11/16/2009---$-16.57---
08/14/2009---$-55.45---
05/19/2009---$-30.34---
02/25/2009---$5.06---
12/03/2008---$-55.53---
08/19/2008---$-56.64---
05/20/2008---$-62.10---
11/14/2007---$-112.50-300.07%
08/14/2007---$-196.87-249.99%
05/15/2007---$-119.73---
11/14/2006---$-84.370.00%
08/14/2006---$-112.500.00%
05/15/2006---$-140.620.00%
09/30/2005---$-118.85---
06/30/2005---$-934.25---
03/31/2005---$-152.43---
12/31/2004---$-196.87---
09/30/2004---$-240.39---
06/30/2004---$-109.61---
03/31/2004---$-140.65---
12/31/2003---$-225.00---
09/30/2003---$-391.61---
06/30/2003---$-93.46---
03/31/2003---$-91.67---
09/30/2002---$-507.41---
06/30/2002---$24.21---
03/31/2002---$-552.10---
09/30/2001---$-1,528.45---
06/30/2001---$-4,513.55---
03/31/2001---$1,855.58---
09/30/2000---$-2,621.34---
06/30/2000---$-7,888.48---
03/31/2000---$-5,766.57---
09/30/1999---$-986.48---
06/30/1999---$-1,929.43---
03/31/1999---$-2,666.06---
09/30/1998---$-5,140.91---
06/30/1998---$695.14---
03/31/1998---$-9,885.89---

More About TG Therapeutics Inc

Website
https://www.tgtherapeutics.com
Country
USA
Full Time Employees
370

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. The company was incorporated in 1993 and is based in Morrisville, North Carolina.

“TG Therapeutics Inc Earnings” Can Refer to the TG Therapeutics Inc Earnings Date

Some people say “TG Therapeutics Inc earnings” as a shortform way to refer to the earnings date.

For example, someone might say, “I plan to hold my TG Therapeutics Inc position through earnings.” That typically means the person is going to hold their position through the upcoming earnings date.

Owning TG Therapeutics Inc Stock on the Earnings Date

If you own TG Therapeutics Inc stock (TGTX) on the earnings date, then you will be exposed to the potential price volatility that often accompanies earnings announcements.

A company’s earnings typically have a big impact on its stock price, which explains why the stock price for TG Therapeutics Inc might exhibit major fluctuations on the day of the earnings announcement. The price fluctuations can go in either direction (up or down), representing a larger potential investment risk and reward than many other days of the year.

There is often a big audience of investors involved with trading TG Therapeutics Inc shares of stock on its earnings day. This means there is typically more trading volume, liquidity, and price volatility on the day earnings are announced.

These features are attractive to some types of active traders who are looking for stocks that exhibit large price movements and substantial volume.

Owning TG Therapeutics Inc Options on the Earnings Date

If you own TG Therapeutics Inc options on the earnings date, then you will be exposed to the potential price volatility that often accompanies earnings announcements.

In addition, the extrinsic values of TG Therapeutics Inc options that overlap earnings dates are often higher than other days of the year. In other words, the premiums you pay to own TG Therapeutics Inc options are typically higher during that period. In particular, they are frequently higher immediately before earnings and on the day they’re announced.

This makes sense considering that prices are often more volatile on earnings dates for TG Therapeutics Inc. That potential volatility is a key factor that affects the premium cost of owning options.

Once the earnings announcement is done and the anticipated price volatility has gone down, the extrinsic values of TG Therapeutics Inc options often go down. This is sometimes referred to as volatility crush.

Learning More TG Therapeutics Inc Earnings

You can contact us any time if you would like to ask questions about TG Therapeutics Inc earnings or anything else related to the stock market.

This site uses cookies to provide you with an optimal user experience. By using StockMarketGuides.com, you accept our use of cookies.